MAbSilico

MAbSilico is a leading TechBio company dedicated to revolutionizing antibody drug design and discovery through advanced AI-based solutions. MAbSilico empowers biotech and pharmaceutical companies to significantly mitigate antibody discovery risks by delivering computationally designed candidates within days. These candidates are meticulously designed and characterized in silico, then rigorously validated using cutting-edge biological technologies.

MAbSilico's innovative approach integrates 3D modeling, interaction simulation, and linear sequence analysis. This allows for precise definition of antibody drug candidates, considering factors such as epitope, affinity, off-target risk, cross-species reactivity, and developability assessment, ensuring readiness for biological activity evaluation. Furthermore, MAbSilico employs NLP technologies to gather comprehensive information about antibodies and their targets from diverse databases, ensuring thorough competitive landscape analysis and freedom to operate for computationally designed antibody candidates. Located in Tours, FR, MAbSilico is positioned to drive advancements in the biotechnology sector.

MAbSilico is committed to providing unparalleled solutions in antibody drug design and discovery. We invite the manager of MAbSilico to create a customized and exclusive company showcase and product listing on our platform to further amplify their market presence and connect with potential partners and clients.